ArticleChemSusChem2026
Toward Cost-Effective and Sustainable Production of 2,5-Bis(hydroxymethyl)furan by an Engineered Alcohol Dehydrogenase EcYjgB.
Article in ChemSusChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
2,5-Bis(hydroxymethyl)furan (BHMF) is a useful intermediate for manufacturing biobased polymers, biofuels, and fine chemicals. Biocatalytic reduction of 5-hydroxymethylfurfural (HMF) obtained via hexoses dehydration is a sustainable route toward BHMF, but the demand for efficient and cost-effective processes remains highly pressing. In this work, cofactor specificity engineering of an alcohol dehydrogenase from Escherichia coli (EcYjgB) was performed to improve its catalytic efficiency toward NADH, thus allowing the use of cheaper formate instead of glucose as the cosubstrate for BHMF production from HMF. Upon two-round mutagenesis, a promising variant V2 (S199D/S200R) was achieved, with greatly improved catalytic efficiencies toward both NADH and HMF as well as with reduced substrate inhibition. The recombinant E. coli strain harboring the variant and formate dehydrogenase displayed a much higher catalytic performance in HMF reduction at the expense of formate, compared to the strain incorporating the wild-type enzyme. The practicability of the variant V2 was demonstrated by preparative-scale synthesis of BHMF at 0.5-1 M substrate loadings with 7.8-9.8 g/L h productivities and >98% yields. According to environmental footprint evaluation and preliminary feedstock cost analysis, the formate-fueled bioprocess may hold great potential for cost-effective and sustainable production of BHMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.